Mallinckrodt Public Limited Company.
MNK.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Mallinckrodt Public Limited Company is a global biopharmaceutical company. It develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies. The company focuses on autoimmune and rare diseases, neurology, and critical care. Mallinckrodt's portfolio includes branded...Show More
Better Health for All
-40
Mallinckrodt faces significant negative findings regarding its pricing and risk transparency. Acthar Gel is priced at nearly $39,000 per vial, vastly exceeding alternatives costing a few dollars, and the company settled for $260 million for overcharging Medicaid for Acthar.
1
Mallinckrodt denied wrongdoing in opioid marketing despite lawsuits for deceptive practices and a $1.7 billion settlement, and its defense of doctor payments for Acthar was questioned due to significant financial conflicts of interest.
2
The company was involved in lawsuits for deceptive marketing of highly addictive generic opioids, but has since implemented an Opioid Product Operating Injunction in 2020 with extensive restrictions, participates in FDA-mandated REMS programs, and expanded a plant for addiction treatment.
3
Mallinckrodt invested 6-7% of its net sales in R&D, including over $650 million in Acthar modernization.
4
The company demonstrates strong healthcare data responsibility, complying with GDPR, CCPA, and HIPAA, and maintaining an information security program.
5
Its clinical trial ethics are robust, adhering to international guidelines, ensuring informed consent, and publicly disclosing results on major registries.
6
Fair Money & Economic Opportunity
0
Mallinckrodt Public Limited Company is a global biopharmaceutical company focused on developing, manufacturing, marketing, and distributing specialty pharmaceutical products and therapies. The company's core business does not involve providing lending, insurance, money movement, or deposit services to consumers. Therefore, the Key Performance Indicators (KPIs) under the 'Fair Money & Economic Opportunity' value, which are designed to assess financial institutions and their consumer financial services, are not applicable to Mallinckrodt's operations. The provided articles confirm the company's focus on pharmaceutical products and related financial performance, but offer no evidence of engagement in consumer financial services relevant to these KPIs.
Fair Pay & Worker Respect
0
Employee reviews from 2023-2025 consistently show an overall employee rating of 3.3 out of 5 stars across platforms like Indeed and Glassdoor, based on hundreds of reviews
1
. This rating translates to approximately 66 out of 100 for worker engagement. While employees frequently praise good pay, benefits, and regular pay increases
2
, they also highlight significant concerns. These include stressful workloads, a lack of flexibility, poor management, and frequent layoffs
3
. Reviews also mention a toxic workplace culture, instances of discrimination, and a perceived lack of appreciation
4
. Some employees report issues with holiday pay and pay scale readjustments, as well as additional responsibilities without corresponding benefits
5
.
Fair Trade & Ethical Sourcing
20
Mallinckrodt explicitly integrates ethical business practices, including human rights, prohibition of child labor, human trafficking, discrimination, and ABAC laws, into 100% of its contracts and agreements with all suppliers and third parties.
1
The company also directs 16.8% of its addressable spend to small and diverse suppliers, engaging with 482 such entities.
2
Honest & Fair Business
0
No evidence available to assess Mallinckrodt Public Limited Company on Honest & Fair Business.
Kind to Animals
0
No specific data or quantitative information regarding Mallinckrodt's animal welfare practices, animal testing, sourcing of animal-derived ingredients, or conservation initiatives was found in the provided article. The article focuses on general corporate sustainability goals without detailing relevant metrics for the 'Kind to Animals' value.
1
No War, No Weapons
0
No evidence available to assess Mallinckrodt Public Limited Company on No War, No Weapons.
Planet-Friendly Business
-40
The company's total Scope 1, 2, and 3 greenhouse gas emissions were 387,292 metric tons CO2e in 2024.
1
It has not publicly committed to specific climate goals through major frameworks like the Science Based Targets initiative (SBTi).
2
In 2024, 8% of its total energy consumption was sourced from renewables.
3
The company achieved an 88% recycling, reclamation, or thermal recovery rate for hazardous waste and 35% for non-hazardous waste in 2024, with its Dublin headquarters receiving Zero-to-Landfill certification.
4
Mallinckrodt US LLC, a related entity, received multiple notices of violation from the Department of Environmental Protection (DEP) for failing to remove mercury-contaminated soil at its Orrington, Maine site, with violations described as "ongoing, daily basis" since at least February 5, 2024.
5
This site was responsible for releasing between 6 and 12 metric tons of mercury in the late 1960s and early 1970s, and the company was ordered to pay at least $187 million in 2022 for cleanup.
6
Respect for Cultures & Communities
0
No evidence available to assess Mallinckrodt Public Limited Company on Respect for Cultures & Communities.
Safe & Smart Tech
-60
Mallinckrodt has a history of significant regulatory compliance issues, including an Operating Injunction agreed to in October 2020
1
and adopted in January 2021,
2
and a 2021 settlement requiring the public disclosure of 1.4 million internal documents.
3
The company also faced DEA pressure to upgrade its suspicious order monitoring procedures.
4
Historically, between 2008 and 2015, Mallinckrodt repurposed data, ostensibly for drug distribution regulation, to inflate sales and identify high-volume opioid prescribers, indicating a pattern of unauthorized data use.
5
User data control is limited by class action and California Civil Code Section 1542 waivers, despite offering basic options to opt out or correct personal information.
6
,
7
The company provides specific online training related to its Operating Injunction,
8
with a passing grade of 80% required,
9
and performs quarterly tests of its Integrity Hotline.
10
Zero Waste & Sustainable Products
-40
Mallinckrodt Chemical Works illegally dumped waste from uranium processing at sites including the West Lake Landfill.
1
, leading to an ongoing lawsuit for remediation costs, with the EPA issuing a $205 million remediation plan.
2
While the EPA is aware Mallinckrodt did not send residues from its government work to West Lake Landfill
3
, the company has incurred $578,499 in penalties for 7 environment-related offenses since 2000
4
, including a 2008 radioactive waste violation
5
and a $449,740 environmental violation in 2013
6
. However, in 2024, no major issues were identified during routine inspections by global regulatory agencies.
7
The company implemented over 10 waste reduction initiatives
8
, such as achieving Zero-to-Landfill certification at its Dublin headquarters in 2024
9
, undertaking waste-to-energy initiatives at multiple sites (including the Raleigh plant burning 97% of hazardous waste for energy)
10
, and engaging in source reduction
11
. Additionally, 88% of hazardous waste was recycled, reclaimed, or thermally recovered in 2024
12
. The company also promotes the safe disposal of unused or expired medications through its membership in the Pharmaceutical Product Stewardship Work Group (PPSWG) and MED-Project USA
13
.